Cannabis News
CBPM: Products for Specific Health Conditions to Enter the Market
For the first time in the UK, distributor Sana Healthcare will launch a new formulation of cannabis-based product medicines (CBPM) targeted at specific health conditions to facilitate clinician prescribing.
Tikun Olam, Little Green Pharma, and Cymra Life Sciences have signed deals with the company to bring products to market with strong indication-specific data.
As part of Sana Healthcare’s formulary, clinicians will be able to choose products with some evidence of efficacy for a variety of conditions, including epilepsy, inflammatory bowel disease, Crohn’s disease, movement disorders, chronic pain, autism, and dementia.
For the first time, Tikun Olam’s Avidekel oil will be available on the UK market, giving doctors access to an unlicensed CBPM that has shown promising results in paediatric epilepsy research.
As well as epilepsy, Avidekel has shown positive results in studies for cerebral palsy and Crohn’s disease.
Cymra Life Sciences has completed a phase II clinical trial for its Cybis formulation in patients with chronic back and neck pain. Results are expected later this year. In 2023, a pivotal phase III trial will be conducted.
Those products join Little Green Pharma’s Classic 10:10 (THC:CBD), which has shown meaningful improvements in pain, sleep, and fatigue in studies of medical cannabis in chronic refractory pain.
CBPM: Confidence and reassurance for clinicians
A team at Sana Healthcare includes chief medical officer, Dr. Steve Hajioff, a former adviser to NICE, NHS England, and the WHO, and managing director, Arjun Rajyagor, a Junior Apprentice winner and tech innovator.
By building trust among clinicians and improving patient outcomes, the company hopes the move will enable the UK market to reach its “full potential.”
Hajioff commented: “At Sana Healthcare we believe that our data-led and indication-specific formulary will give confidence and reassurance to clinicians in prescribing cannabis-based medicines where appropriate.
Clinicians must be provided with the information they need to prescribe confidently and safely in a way that builds trust in the effectiveness of CBPM.
“This is what will ultimately allow patients across the country to access new, effective, and potentially life-changing cannabis-based medicines.”
